- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00397787
Sunitinib in Treating Patients With Metastatic Pancreatic Cancer That Progressed After First-Line Therapy With Gemcitabine
A Phase II Study of Sunitinib Malate (SU11248, NSC #736511, IND #74,019) in Patients With Previously Treated Pancreatic Adenocarcinoma With Measurable Metastatic Disease Following Progression on Front-Line Gemcitabine-Based Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To determine the response rate to sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma.
SECONDARY OBJECTIVES:
I. To determine the duration of response, progression-free survival and overall survival of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma.
II. To determine the safety of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma.
OUTLINE: This is a multicenter, nonrandomized study.
Patients receive oral sunitinib malate daily on days 1-28. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
After completion of study, patients are followed every 3 months until 2 years from study entry or until disease progression.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60606
- Cancer and Leukemia Group B
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan Kettering Cancer Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Histologic or cytologic documentation of pancreatic adenocarcinoma with evidence of disease progression following first-line therapy is required
- No brain metastases
Patients with measurable disease
- Lesions that can be accurately measured in at least one dimension (longest diameter to be recorded as >= 20 mm with conventional techniques or as>= 10 mm with spiral computed tomography (CT) scan; of particular note, the primary pancreatic tumor does not constitute measurable disease; therefore, patients with locally advanced pancreatic cancer as the sole site of disease are not eligible
Patients must have received one of the following prior therapies containing gemcitabine:
- One and only one prior therapy for metastatic disease with gemcitabine, or a gemcitabine-containing cytotoxic combination, or
- One prior chemoradiation therapy containing gemcitabine for inoperable locally advanced pancreatic cancer, as long as the patient has subsequently progressed and has measurable disease outside a radiation port, or
- One prior adjuvant chemotherapy regimen or chemoradiation therapy containing gemcitabine if the patient subsequently progressed within 3 months of completion of adjuvant therapy; patients who have received chemoradiation in the adjuvant setting must have measurable disease outside the radiation port
- No prior therapy with any other antiangiogenic agent (e.g., bevacizumab, sorafenib, pazopanib, AZD2171, PTK787, VEGF Trap, etc.)
- At least 4 weeks must have elapsed prior to initiation of treatment since the completion of chemotherapy and/or radiation therapy
- At least 4 weeks must have elapsed prior to registration since any major surgery
- Prior erlotinib is permitted; the last dose must have been administered 14 or more days prior to initiation of treatment; all erlotinib related side effects must have resolved to < grade 1 prior to registration
No significant cardiac disease including:
- QTc prolongation (defined as a QTc interval equal to or greater than 500 msec) or other significant EKG abnormalities
- History of myocardial infarction, cardiac arrhythmia, stable/unstable angina, symptomatic congestive heart failure, or coronary/peripheral artery bypass graft or stenting within 12 months prior to registration
- History of class III or IV heart failure within 12 months prior to registration as defined by the NYHA functional classification system
- In addition, patients with history of hypertension must be well controlled (< 140/90) on a regimen of anti-hypertensive therapy
- Patients with a history of hypothyroidism are eligible, provided they are currently euthyroid
The use of inhibitors and inducers of CYP3A4 is not permitted:
The following inhibitors of CYP3A4 is prohibited within 7 days before beginning and during treatment with sunitinib:
- Azole antifungals (ketoconazole, itraconazole)
- Diltiazem
- Clarithromycin
- Erythromycin
- Verapamil
- Delavirdine
- HIV protease inhibitors (indinavir, saquinavir, ritonavir, atazanavir, nelfinavir)
The following inducers of CYP3A4 are prohibited within 12 days before beginning and during treatment with sunitinib:
- Rifampin
- Rifabutin
- Carbamazepine
- Phenobarbital
- Phenytoin
- St. John's wort
- Efavirenz
- Tipranavir
- Other inhibitors or inducers of CYP3A4 may be used if necessary, but their use is discouraged
- The use of agents with proarrhythmic potential (e.g., quinidine, procainamide, disopyramide, sotalol, probucol, bepridil, haloperidol, risperidone, indapamide, flecainide) is not permitted during the study
- ECOG performance status 0-2
- No history of cerebrovascular accident (CVA) or transient ischemic attack within 12 months prior to registration
- No history of pulmonary embolism within the past 6 months
- Patients who require use of therapeutic doses of coumadin-derivative anticoagulants such as warfarin are excluded, although doses of up to 2 mg daily are permitted for prophylaxis of thrombosis; Note: Low molecular weight heparin is permitted provided the patient's PT INR is < 1.5
- No serious or non-healing wound, ulcer, or bone fracture
- No history (within 6 months) of significant bleeding events (e.g., upper or lower GI bleeding, hemoptysis, or hematuria), abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 28 days of treatment
- No evidence of duodenal invasion by the tumor on CT scan
- No "currently active" second malignancy other than non-melanoma skin cancers; patients are not considered to have a "currently active" malignancy if they have completed therapy and are considered by their physician to be at less than 30% risk of relapse
- Non-pregnant and not breast feeding; pregnant women are excluded from this study because sunitinib is an antiangiogenic agent with the potential for teratogenic or abortifacient effects; because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with sunitinib, breastfeeding should be discontinued if the mother is treated with sunitinib malate
- ANC >= 1,500/μl
- Platelet count >= 100,000/μl
- Bilirubin < 1.5 mg/dL
- PT and PTT =< 1.5 X ULN
- Creatinine =< 1.5 mg/dL
- AST (SGOT) =< 2.5 X ULN if no liver metastases (=< 5 X ULN if liver metastases)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Treatment (sunitinib malate)
Patients receive oral sunitinib malate daily on days 1-28.
Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Response (CR/PR/stable disease) as measured by RECIST criteria
Time Frame: At 6 weeks post-initiation of protocol treatment
|
At 6 weeks post-initiation of protocol treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Response duration
Time Frame: Up to 2 years
|
Duration of response will be determined for the subset of patients who achieve a confirmed response of CR or PR.
Duration of objective response will be defined as the time from the first tumor assessment indicating response (later confirmed) to the time of disease progression or death from any cause.
|
Up to 2 years
|
Progression-free survival (PFS)
Time Frame: Up to 2 years
|
Median and 1-year survival will be assessed using Kaplan-Meier methods.
|
Up to 2 years
|
Number and percentage of patients reporting common and serious adverse events (AEs), the AEs related to sunitinib, reason for study discontinuation, clinically significant laboratory abnormalities, and AEs with worst NCI CTCAE grade
Time Frame: Up to 2 years
|
Summarized descriptively for all patients receiving at least one dose of sunitinib.
|
Up to 2 years
|
Overall survival (OS)
Time Frame: Up to 2 years
|
Median and 1-year survival will be assessed using Kaplan-Meier methods.
|
Up to 2 years
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Eileen O'Reilly, Cancer and Leukemia Group B
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Digestive System Neoplasms
- Endocrine Gland Neoplasms
- Pancreatic Diseases
- Adenocarcinoma
- Pancreatic Neoplasms
- Carcinoma, Acinar Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Sunitinib
Other Study ID Numbers
- NCI-2012-02823
- U10CA031946 (U.S. NIH Grant/Contract)
- CALGB-80603
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acinar Cell Adenocarcinoma of the Pancreas
-
Mohammed Najeeb Al HallakNational Cancer Institute (NCI)CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IV Pancreatic CancerUnited States
-
National Cancer Institute (NCI)TerminatedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IV Pancreatic CancerUnited States
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)TerminatedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic Cancer | Stage IIB Pancreatic CancerUnited States
-
John DeWittAmerican Society for Gastrointestinal Endoscopy; Pinnacle Biologics Inc.CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage III Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterCompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage I-III Pancreatic CancerUnited States
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic CancerUnited States
-
Yale UniversityNational Cancer Institute (NCI)Active, not recruitingAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage I Pancreatic CancerUnited States
-
Mayo ClinicCompletedUnspecified Adult Solid Tumor, Protocol Specific | Acinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage IV Pancreatic CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedAcinar Cell Adenocarcinoma of the Pancreas | Duct Cell Adenocarcinoma of the Pancreas | Recurrent Pancreatic Cancer | Stage III Pancreatic Cancer | Stage II Pancreatic CancerUnited States
Clinical Trials on sunitinib malate
-
PfizerCompletedGastrointestinal Stromal TumorsKorea, Republic of
-
PfizerCompletedGastrointestinal Stromal TumorsUnited States, Czechia, France
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)CompletedKidney CancerUnited States
-
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.CompletedRenal Cell Carcinoma | Gastrointestinal Stromal Tumors | Pancreatic Neuroendocrine TumorChina
-
PfizerCompletedCarcinoma, Renal CellUnited States
-
Icahn School of Medicine at Mount SinaiPfizerCompleted
-
Sidney Kimmel Cancer Center at Thomas Jefferson...PfizerActive, not recruitingSunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal MelanomaCiliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage IIIC Intraocular Melanoma | Stage I Intraocular Melanoma | Stage IIA Intraocular Melanoma | Stage IIB Intraocular... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedClear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney CarcinomaUnited States
-
Tony Bekaii-SaabPfizerCompletedEsophageal CancerUnited States
-
California Pacific Medical Center Research InstitutePfizer; University of California, San FranciscoCompleted